{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T17:10:04Z","timestamp":1738343404975,"version":"3.35.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.2515\/therapie:2008034","type":"journal-article","created":{"date-parts":[[2008,8,22]],"date-time":"2008-08-22T11:11:35Z","timestamp":1219403495000},"page":"237-242","source":"Crossref","is-referenced-by-count":3,"title":["Markers of D2 and D3 Receptor Activity in vivo: PET Scan and Prolactin"],"prefix":"10.1016","volume":"63","author":[{"given":"Nitza","family":"Thomasson-Perret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Fran\u00e7ois","family":"P\u00e9n\u00e9laud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Th\u00e9ron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Gouttefangeas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Moca\u00ebr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2008034_bb0010","first-page":"503","article-title":"The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development","volume":"12","author":"Talbot","year":"2002","journal-title":"European Neuro-psychopharmacology"},{"key":"10.2515\/therapie:2008034_bb0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1192\/S0007125000296888","article-title":"PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients","volume":"160","author":"Farde","year":"1992","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.2515\/therapie:2008034_bb0020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008034_bb0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF02245614","article-title":"The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88, 059-01) determined by positron emission tomography","volume":"124","author":"Bench","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.2515\/therapie:2008034_bb0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1095\/biolreprod36.1.47","article-title":"Interactions between prolactin and dopaminergic neurons","volume":"36","author":"Moore","year":"1987","journal-title":"Biol Reprod"},{"key":"10.2515\/therapie:2008034_bb0035","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF00429215","article-title":"Clozapine: plasma levels and prolactin response","volume":"73","author":"Kane","year":"1981","journal-title":"Psychopharmacology"},{"key":"10.2515\/therapie:2008034_bb0040","first-page":"107","article-title":"Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204, 636)","volume":"32","author":"Hamner","year":"1996","journal-title":"Psychopharmacol Bull"},{"key":"10.2515\/therapie:2008034_bb0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(97)00036-4","article-title":"The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations","volume":"26","author":"Crawford","year":"1997","journal-title":"Schizophr Res"},{"key":"10.2515\/therapie:2008034_bb0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1176\/appi.ajp.159.1.133","article-title":"Elevation of prolactin levels by atypical antipsychotics","volume":"159","author":"Turrone","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008034_bb0055","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"13","key":"10.2515\/therapie:2008034_bb0060","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1359-6446(05)03491-4","article-title":"Dopamine D3 receptor antagonists as therapeutic agents","volume":"10","author":"Joyce","year":"2005","journal-title":"Drug Discov Today"},{"issue":"3","key":"10.2515\/therapie:2008034_bb0065","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","article-title":"Extrapyramidal symptoms with atypical antipsychotics. Incidence, prevention and management","volume":"28","author":"Pierre","year":"2005","journal-title":"Drug Safety"},{"key":"10.2515\/therapie:2008034_bb0070","first-page":"473","article-title":"Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications","volume":"175","author":"Frankle","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.2515\/therapie:2008034_bb0075","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1176\/appi.ajp.158.6.926","article-title":"No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457","volume":"158","author":"Talvik","year":"2001","journal-title":"Am J psychiatry"},{"key":"10.2515\/therapie:2008034_bb0080","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.expneurol.2004.03.022","article-title":"Selective blockade of D3 dopamine receptors enhances the antiparkinsonian properties of ropini-role and levodopa in the MPTP-lesioned primate","volume":"188","author":"Silverdale","year":"2004","journal-title":"Exp Neurol"},{"key":"10.2515\/therapie:2008034_bb0085","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0960-894X(99)00312-1","article-title":"Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist","volume":"9","author":"Dubuffet","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"10.2515\/therapie:2008034_bb0090","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1124\/jpet.107.126706","volume":"324","author":"Millan","year":"2008","journal-title":"J of Pharmacol Exp Therapeutics"},{"key":"10.2515\/therapie:2008034_bb0095","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1176\/appi.ajp.160.8.1413","article-title":"Is regionally selective D2\/ D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]Epidepride SPET study of amisulpride-treated patients","volume":"160","author":"Bressan","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008034_bb0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pnpbp.2004.10.010","article-title":"Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol","volume":"29","author":"Corripio","year":"2005","journal-title":"Progr Neuro-Psychopharmacol & Biol Psychiatry"},{"issue":"5","key":"10.2515\/therapie:2008034_bb0105","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14656566.6.5.803","article-title":"Risperidone: a review","volume":"6","author":"M\u00f6ller","year":"2005","journal-title":"Expert Opinion Pharmacotherapy"},{"key":"10.2515\/therapie:2008034_bb0110","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/jpet.107.132563","volume":"324","author":"Millan","year":"2008","journal-title":"J of Pharmacol Exp Therapeutics"},{"key":"10.2515\/therapie:2008034_bb0115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0031-6997(24)01327-9","article-title":"The D3 dopamine receptor: neurobiology and potential clinical relevance","volume":"49","author":"Levant","year":"1997","journal-title":"Pharmacol Rev"},{"key":"10.2515\/therapie:2008034_bb0120","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0149-7634(01)00023-9","article-title":"D3 Dopamine receptor, behavioral sensitization, and psychosis","volume":"25","author":"Richtand","year":"2001","journal-title":"Neurosci Biobehav Rev"},{"key":"10.2515\/therapie:2008034_bb0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0163-7258(01)00139-5","article-title":"Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs","volume":"90","author":"Joyce","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.2515\/therapie:2008034_bb0130","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.2515\/therapie:2008034_bb0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00001504-200101000-00005","article-title":"Antipsychotic drug treatment: recent advances","volume":"14","author":"Barnes","year":"2001","journal-title":"Curr Opin Psychiatr"},{"issue":"Suppl.","key":"10.2515\/therapie:2008034_bb0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571630556X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571630556X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T16:45:31Z","timestamp":1738341931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059571630556X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S004059571630556X"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2008034","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}